Dravet syndrome (DS) is a rare epileptic encephalopathy that is diagnosed in early infancy and extends through adulthood. Fenfluramine (FFA) is a recently licensed add-on therapy for the treatment of seizures in patients with DS aged 2 years and older.
This work presents a novel individual-level simulation modelling approach to calculate the cost-effectiveness of FFA compared with cannabidiol plus clobazam as an add-on therapy for DS patients in England. Results indicate that FFA is a cost-effective intervention.
Weston G, Pinsent A, Adams EJ, Linley W, Hawkins N, Schwenkglenks M, Hamlyn Williams C, Toward T. A Cost-Effectiveness Analysis of Fenfluramine for the Treatment of Seizures for Patients with Dravet Syndrome (DS) in the UK Setting. Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2021 Congress, May 17 – 20, 2021; Virtual
Fatal error: Uncaught Error: Call to undefined function get_field() in /home/u572422322/staging.aquariusph.com/web/app/themes/hello-elementor-child/single-jetpack-portfolio.php:33 Stack trace: #0 /home/u572422322/staging.aquariusph.com/web/wp/wp-includes/template-loader.php(106): include() #1 /home/u572422322/staging.aquariusph.com/web/wp/wp-blog-header.php(19): require_once('/home/u57242232...') #2 /home/u572422322/staging.aquariusph.com/web/index.php(6): require('/home/u57242232...') #3 {main} thrown in /home/u572422322/staging.aquariusph.com/web/app/themes/hello-elementor-child/single-jetpack-portfolio.php on line 33